Cognition Therapeutics is a clinical-stage biopharmaceutical company leveraging our expertise in the σ-2 (sigma-2) receptor to develop innovative, small molecule therapeutics targeting age-related degenerative diseases. Our initial focus is on degenerative diseases of the CNS and retina such as Alzheimer’s disease, dementia with Lewy bodies and dry age-related macular degeneration.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMC
May 23, 2023
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer’s Disease
May 18, 2023
May 04, 2023
Jun 12 - Jun 14, 2023
Apr 13, 2023
Mar 28 - Apr 1, 2023
Latest SEC Filings
Report of unscheduled material events or corporate event
Quarterly report which provides a continuing view of a company's financial position
Initial filing by director officer or owner of more than ten percent.